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developed with a time horizon of 40 years. Transition probabil-
ities for macrovascular and microvascular complications were
drawn from the UKPDS 68 Outcomes equations. Direct costs
and quality of life (EQ5D) were derived from published sources
and the HODaR database respectively; costs and beneﬁts were
discounted annually at 3.5%. This model was adapted for Type
2 patients switched from NPH to glargine identiﬁed from 
the THIN database, a UK primary care database including
2,335,667 active patients recorded over 15 years from 211 prac-
tices. Analysis was conducted on a total of 181 patients with
data for the 12 month period prior to and post switch to
glargine; the primary outcome measure was Hba1c change.
RESULTS: The median age at switch from NPH was 71 with
mean duration of T2DM of 9.2 years. Baseline HbA1c was
8.79% and patients switching to glargine showed a signiﬁcant
reduction in HbA1c of 0.67%(p = 0.00384) between switch to
glargine and 12 months post glargine initiation. Incorporating
this into a simulated cohort of 10,000 patients followed over a
40 year time horizon translated into 150 fewer cardiovascular
events. Average cost per patient was ≤4338 and ≤3370 for
glargine and NPH respectively, providing discounted quality
adjusted life years (QALYs) of 4.96 and 4.86 respectively; result-
ing in a discounted incremental cost effectiveness ratio (ICER)
of ≤9200 per QALY. CONCLUSION: Based on UK real life
observational data, switching to basal insulin in type 2 DM
patients from NPH to glargine is cost-effective; with a corre-
sponding ICER within accepted thresholds for cost-effective
treatments.
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OBJECTIVES: The purpose of this study was to evaluate the cost
effectiveness (cost utility) of insulin glargine in the UK for people
with Type 1 diabetes mellitus (T1DM) using observational data
in patients continuing on NPH versus those switching from NPH
to insulin glargine. METHODS: A discrete event simulation
model was developed with a time horizon of 40 years. Transi-
tion probabilities for progression to microvascular complications
were derived from the DCCT (Diabetes Control and Complica-
tions Trial) with cardiovascular events modelled via the Fram-
ingham equations. Direct costs and quality of life (EQ5D) were
derived from published sources and the HODaR database
respectively; costs and beneﬁts were discounted annually at
3.5%. The model was adapted to the proﬁle of T1DM patients
switched from NPH to glargine identiﬁed via the THIN database
(The Health Improvement Network), a UK primary care data-
base including 2,335,667 active patients recorded over 15 years.
Analysis was conducted on a total of 466 patients with data for
the 12 month period prior to, and post switch; the primary
outcome measure of Hba1c change. RESULTS: The median age
of patients switched from NPH to glargine was 33 years with
mean duration of T1DM of 8.1 years. Baseline HbA1c was
8.71% and patients switching to glargine showed a reduction in
HbA1c of 0.27% between switch and 12-months post initiation.
Over 40 years, in a simulated cohort of 10,000 there were 523
fewer fatal microvascular complications and, on average, 1 less
microvascular complication per patient in those receiving
glargine compared to NPH. The discounted incremental cost
effectiveness ratio (ICER) was £6527 per quality adjusted life
year (QALY) gained. CONCLUSION: Based on UK real life
observational data, switching to basal insulin in type 1 DM
patients from NPH to glargine is cost-effective; with a corre-
sponding ICER well within accepted thresholds for cost-effective
treatments.
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OBJECTIVES: Outcomes in type 2 diabetes patients can differ
based on the antidiabetic medication that is used. Thiazolidine-
diones (TZD) are a newer class of agents used for type 2 dia-
betes treatment. Previously, no study has compared health care
utilization associated with the two TZDs on the market. The
objective of this study was to compare health care utilization
between two TZDs used by Medicaid-enrolled patients with type
2 diabetes. METHODS: This was a retrospective data analysis
comparing cohorts of patients with type 2 diabetes starting a new
antidiabetic medication for hospitalizations, emergency room
visits, outpatient visits, and health care costs. A total of 660
patients starting rosiglitazone between July 1, 2001 to June, 30,
2002 were compared to 1045 patients staring pioglitazone
during the same period. The patients were followed up for 30
months to examine the difference in health care utilization over
time. Multivariate regression techniques were employed for com-
parisons between different antidiabetic therapies. RESULTS:
Multivariate analysis showed that rosiglitazone group was asso-
ciated with almost 12% decrease in the mean number of hospi-
talizations, and 10 % decrease in the mean number of emergency
room visits, and a 7.3% decrease in total health care costs 
as compared to the pioglitazone group (all p < 0.05). CON-
CLUSION: Introduction of rosiglitazone was associated with
decreased number of hospitalizations, emergency room visits,
and total health care costs compared to pioglitazone. The uti-
lization of oral antidiabetic agents, with documented clinical and
economic beneﬁts, should continue to be advocated to reduce
avoidable medical care utilization, and improve patient out-
comes in this population.
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OBJECTIVES: Diabetes is the sixth leading cause of death in the
United States, and its prevalence has been increasing. The annual
cost of this illness to society reached close to $100 billion in
1999. The objective of this study is to analyze the trends of price
and utilization of oral anti-diabetic medications in U.S. state
Medicaid programs. METHODS: Oral anti-diabetic drugs
include ﬁrst- and second-generation sulfonylureas, α-glucosidase
inhibitors, biguanides, thiazolidinediones, meglitinides, and
combination drugs. Data were taken from the national Medic-
aid pharmacy claims databases for 1991 to 2005, provided by
the Centers for Medicare & Medicaid Services. Descriptive time-
series analysis was used to assess quarterly prescription numbers,
amount of reimbursement, and cost per prescription. RESULTS:
